{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-000640","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2023-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.961513+00:00","generated_at":"2026-06-20T20:09:40.020291+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BrainStorm promotes Dr. Lindborg to Co-CEO; Dr. Kern retires as CMO with separation package","bullets":["Dr. Stacy Lindborg appointed Co-CEO, base salary $500K, annual bonus 40% of salary, 250K RSU equity grant.","Dr. Ralph Kern retires as President and CMO effective Jan 20, 2023; receives $250K severance, 150K shares, $125K prorated bonus.","Unvested equity that would vest within six months accelerates for Dr. Kern upon separation.","Dr. Kern to join Scientific Advisory Board at $450/hour, up to 10 hours/month, for two-year term."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-000640","json":"https://secwatch.observer/filing/0001104659-23-000640.json","markdown":"https://secwatch.observer/filing/0001104659-23-000640.md","text":"https://secwatch.observer/filing/0001104659-23-000640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/0001104659-23-000640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/tm231494d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T20:09:40.020291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c98b8ea20","claim":"Dr. Ralph Kern departed as President and Chief Medical Officer at BRAINSTORM CELL THERAPEUTICS INC..","evidence_excerpt":"Effective as of January 3, 2023, the Kern Separation Amendment terminates the employment agreement previously entered into between the Company and Dr. Kern on February 28, 2017.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/0001104659-23-000640-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"President and Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"8d73033e5c","claim":"Dr. Stacy Lindborg was appointed as Co-Chief Executive Officer at BRAINSTORM CELL THERAPEUTICS INC..","evidence_excerpt":"Dr. Lindborg will be appointed to the position of Co-Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/0001104659-23-000640-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Co-Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}